Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 511 participants.
Also called NCT01984424
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 511 participants
- Sponsor
- Registry
-
NCT01984424 -
2013-000935-29
-
- Other papers using this trial's data
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Denmark, France, Germany, Italy, Netherlands, New Zealand, Norway, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01984424. Randomized; quadruple masking; primary purpose treatment. Start 2013-12-10 (actual); primary completion 2015-11-10 (actual). Results posted on 2018-03-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
- Acronym
- GAUSS-3
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Placebo to Atorvastatin
- Intervention (Other)
- Placebo to Ezetimibe
- Intervention (Drug)
- Ezetimibe
- Intervention (Other)
- Placebo to Evolocumab
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01984424- Content hash
371377ec3614db85174a4d9797439a6f6d6711c0754fbfad028239addc81f57c